Navigation Links
An invitation to Europe's largest forum on breast cancer
Date:3/25/2008

What is EBCC?

The most exciting breast cancer conference in Europe, it is the only one that involves all the major players in breast cancer. The conference encourages interaction and collaboration between clinicians, scientists and patients in a partnership of equals to talk not just about scientific advances, but also the ethical, social, political, and practical issues associated with caring for patients with breast cancer. EBCC-6 is expected to attract over 5000 delegates from around 90 countries worldwide.

Here is a sample of the new results to be announced at the conference (embargoed to time of presentation at EBCC-6):

  • Hereditary breast cancer a high cost to patient and healthcare provider alike; why women may choose prophylactic mastectomy rather than go through years of stressful screening programmes

  • How obese women are doubly disadvantaged; they do worse in both breast cancer treatment and diagnosis

  • MRI before surgery can lead to better adapted treatment for breast cancer; should this become a standard procedure"

  • Pregnant patients lose out in breast cancer treatment; a new approach is needed

  • New chemotherapy combo produces side effects, but no extra efficacy, in early breast cancer patients

  • Are aromatase inhibitors associated with increased heart problems" Important new evidence

  • New type of drug shrinks primary breast cancer tumours significantly in just six weeks; research provides leads to a new target in breast cancer treatment the stem cell

  • Chemotherapy for metastatic breast cancer: does it work best against sporadic tumours, or those associated with a BRCA1/2 genetic mutation"

  • Breast cancer screening: is an annual mammogram better than a three-yearly one, and should women continue to be screened up to the age of 75" New evidence

  • Can acupuncture provide effective relief from hot flushes in women who are suffering menopause-like symptoms as a result of taking tamoxifen"

  • Results from the largest multi-centre trial to investigate the combination of trastuzumab and neoadjuvant chemotherapy for women with HER2 positive tumours provides surprising new data on safety and efficacy

  • New study reveals that countries could save millions of Euros on follow-up care for breast cancer patients

  • Breast tumours behave differently depending on whether women are older or younger than 70. Is the immune system involved"

Media briefings:

There will be news briefings in English on Wednesday (10am), Thursday (10am) and Friday (9am) and in German on Wednesday (11am).


'/>"/>
Contact: Mary Rice
mary@mrcommunication.org
ECCO-the European CanCer Organisation
Source:Eurekalert

Related medicine news :

1. Superstar John McEnroe to Highlight The Kennedy Funding Invitational Tennis Tournament, July 9-13, 2008
2. SURGEX(TM) Joins the Team of Sponsors for the PGA Tours 2008 Arnold Palmer Invitational Presented by MasterCard
3. Spartan Stores Becomes Largest U.S. Supermarket Chain to Receive NSF Shop Fresh(TM) Certification
4. CVS, Americas Largest Pharmacy Chain, Pays Nearly $37 Million to Settle Federal and State Generic Drug Switching Charges
5. Grassini & Wrinkle Law Firm Are Awarded Largest PI Verdict in Ventura County History
6. Medco Breaks Ground For Worlds Largest Automated Pharmacy
7. Cardiac Science Delivers Largest Order of Electrocardiograph Systems in Company History
8. AMSA Annual Convention: Largest Gathering of Medical Students Celebrates 58 Years of Student Activism
9. McGraw-Hill Professional Enters Partnership with American College of Physicians, the Worlds Largest Internal Medicine Organization
10. Netsmart Technologies Acquires Largest Provider of Software for Private Practice Mental Health Providers and Therapists
11. Crdentia Selected by Leading Staffing Vendor to Provide Health Care Staffing Services to One of the Largest Hospital Chains in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... An in-depth computational analysis of ... of Pittsburgh points to eight genes that may explain why susceptibility to one of ... results of a study published today in the journal npj Schizophrenia. , “There ...
(Date:2/24/2017)... ... February 24, 2017 , ... Healthcare Associates of ... Center at Craig Ranch building at 8080 State Highway 121, Suite 210, McKinney, Texas ... easy access to Highway 121. , As the practice has grown, the need for ...
(Date:2/24/2017)... ... February 24, 2017 , ... The International Association of Eating Disorders Professionals ... What You See” body image mannequin art competition. Selected from 15 submissions from around ... winner revealed at the 31st annual iaedp Symposium, March 22 – 26 in Las ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... again hosted their Military Wedding Giveaway, with the winning couple announced on Feb. ... with services generously donated from local vendors: A Matter of Taste, Ryan Rousseau ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... with a clinician-based audience, will be participating in Rare Disease Day events, hosted ... D.C. In addition, Rare Disease Report, a website, weekly e-newsletter and quarterly publication, ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... and Strategies - 2016" report to their offering. ... The latest research Autism ... pricing data and benchmarks in the global Autism Spectrum Disorder market. ... What are the key drugs marketed for Autism Spectrum Disorder ...
(Date:2/23/2017)... Limited, ( ASX: ITD ), an innovative diversified healthcare company, is ... December 2016 compared with the previous corresponding period. A full "Results ... . Highlights Profit after ... Earnings per share of 2.2 cents (Dec 2015: 1.2 cents; up ... 11%) Profit before tax of $2.12m (Dec 2015: ...
(Date:2/23/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The latest research Oesophageal Cancer Drugs Price Analysis ... the global Oesophageal Cancer market. The research answers the ... drugs marketed for Oesophageal Cancer and their clinical attributes? How are ...
Breaking Medicine Technology: